0

Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms

Xinyu Yang, Xinye Li, Mengchen Yuan, Chao Tian, Yihan Yang, Xiaofeng Wang, Xiaoyu Zhang, Yang Sun, Tianmai He, Songjie Han, Guang Chen, Nian Liu, Yonghong Gao, Dan Hu, Yanwei Xing, Hongcai Shang

Front Pharmacol. 2018 Oct 16;9:1058.

PMID: 30386232

Abstract:

Some well-established immunotherapy, radiotherapy, postoperation, anticancer drugs such as anthracyclines, antimetabolites, human epidermal growth factor receptor 2 blockers, tyrosine kinase inhibitors, alkylating agents, checkpoint inhibitors, and angiogenesis inhibitors, are significantly linked to cardiotoxicity. Cardiotoxicity is a common complication of several cancer treatments. Some studies observed complications of cardiac arrhythmia associated with the treatment of cancer, including atrial fibrillation (AF), supraventricular arrhythmias, and cardiac repolarization abnormalities. AF increases the risk of cardiovascular morbidity and mortality; it is associated with an almost doubled risk of mortality and a nearly 5-fold increase in the risk of stroke. The occurrence of AF is also usually researched in patients with advanced cancer and those undergoing active cancer treatments. During cancer treatments, the incidence rate of AF affects the prognosis of tumor treatment and challenges the treatment strategy. The present article is mainly focused on the cardiotoxicity of cancer treatments. In our review, we discuss these anticancer therapies and how they induce AF and consequently provide information on the precaution of AF during cancer treatment.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR4248735 Checkpoint Kinase 2, Active human Checkpoint Kinase 2, Active human Price
qrcode